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of transaminases in blood serum and presence of anti HCV
and HCVRNA in the blood.
The positive response to alpha-2a interferon therapy was
found in 20 patients. Of them GNB3 gene was determined
in 3 (15%) patients. In the patients resistant to therapy or
with disease recurrence after antiviral therapy GNB3 C825T
allele was revealed in 12 (60%) patients.
According to our investigations we found increase in number
of GNB3 C825T carriers among the patients without response
to the antiviral treatment.
PP-140 Frequency of hepatitis C virus infection
in Pakistani patients with type 2
diabetes mellitus
N. Jadoon1 *, A. Shahzad1, R. Yaqoob1. 1Nishtar Medical
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Background: There is an increasing evidence of a possible
epidemiological link between HCV infection and diabetes.
It is not known whether such a relationship exists in
patients here as well. We, therefore, investigated the
prevalence of HCV infection in diabetic patients in order to
elucidate the presence of a possible association between
the two endemics in this region. We wanted to compare
the prevalence of HCV infection in diabetic patients with a
sample form general population.
Methods: This cross-sectional study was carried out on 550
diabetes patients seen at diabetes clinic at Nishtar Hospital,
Multan during winter 2008. Patients’ diabetic status and HCV
antibody presence were noted. The control group comprised
of 550 volunteer blood donors attending the blood bank of
Nishtar Hospital, Multan during the period of study. Informed
consent was taken before taking the data. Data Analysis was
done using SPSS v16.
Results: The mean age of patients was 47.58 years while
the mean duration of diabetes was 7.02 years. The patients
were predominantly female (55.27%). Out of 550 patients
whose data was gathered, 86 patients were tested positive
for HCV antibody presence as compared to control in whom
45 people were infected with hepatitis C virus infection out
of 550 (OR = 4.60, 95%CI = 3.22 6.57, p < 0.01). No signiﬁcant
association was found between the duration of diabetes and
presence of HCV infection.
Conclusion: Hepatitis C virus infection is highly prevalent
among type 2 diabetic patients as compared to the control
group in this region. The nature of association and the
effects of other confounding factors need to be seen. It
remains to be elucidated how this co morbidity effects
progression of liver disease and diabetes.
PP-141 Prevalence of gallstones among persons with
chronic liver disease in Pakistan
A. Baig1 *, S. Memon1. 1Isra University Hospital, Pakistan
Background: We determined the association between
Chronic liver disease and Gallstones in a representative
sample of adults in Pakistan.
Methods: We included all the consecutive adults with
HCV antibody positive and HBsAg positive, who visited our
hepatology clinic from Jan 2009 to March 2009. We noted
the status and duration of disease, weight, BMI, associated
DM (Diabetes Mellitus), smoking, ethnicity and number of
children in case of women.
Result: There were 344 participants, out of them 289
(84%) were HCV antibody positive and 55 (16%) were HBsAg
positive. Overall prevalence of gallstones was 14.8%. 84.3%
of gallstones were among HCV antibody positive and 15.7%
among HBsAg positive individuals. Gallstones prevalence
increased with age with a predominance in patients of
more than 40 years of age (P value = 0.003). The frequency
of gallstones increased with the duration of liver disease
(P value = 0.05), peak was seen in patients who had chronic
liver disease for 2 4 years.
Conclusion: Chronic liver disease was strongly associated
with gallstones among men but not in women in our study
in Pakistan and gallstone was more common in adults with
increasing age and severity of liver disease.
PP-142 Clinical relevance of serum HCV core antigen
level and antiviral therapy response
Y.-Z. Zhang1 *, W.-J. Wu1, H. Jin1, Y.-Y. Liu1, Y.-W. Hu1,
Y.-X. Zhang1. 1Shanghai Public Health Clinical Center
Afﬁliated to Fudan University, China
Aim: To evaluate the signiﬁcance of HCV core antigen
detection in the determination of the efﬁcacy of HCV
antiviral therapy in China.
Methods: HCV core antigen was measured in sera of 35
chronic hepatitis C patients. Concentrations of HCV core
antigen and HCVRNA were analyzed at 4 time points before,
during and after the end of antiviral therapy.
Results: This study showed that the HCV core antigen
and HCVRNA concentrations in 35 HCV patients were
signiﬁcantly related. Decrease of HCV core antigen and
HCVRNA concentrations at 4th wk, 24th wk, 48th wk
were observed during antiviral therapy. HCV core antigen
at week 24 of therapy was signiﬁcantly lower than at
week 4 (P= 0.000). In contrast, no decrease was observed in
HCVRNA concentrations in the same time (P= 0.303). HCV
core antigen testing may be advantageous in some cases,
especially the negativity of HCV core antigen at week 4 for
prediction of non-response is reliable.
Conclusion: HCV core antigen represents a stable and
sensitive marker of viral replication, can be used to monitor
the clinical efﬁcacy of HCV antiviral therapy.
Author contribution: Wen-Juan Wu and Yun-Zhi Zhang
contributed equally to this work.
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Background: 17% of Mongolian population is infected with
HCV, which makes the country one of the top HCV infected
countries in the world. Though HCV quantiﬁcation method
was developed almost a decade ago it was only in 2009,
when it was ﬁrst introduced in Mongolia.
Method: Total of HCV 212 patients were enrolled in the
study, all of whom had HCV quantiﬁcation at Happy Veritas
clinical laboratory. HCV quantiﬁcation (Taqman real-time
PCR method) was performed by ABI7000. Applied Bio-
systems, USA. Commercially available HCV quantiﬁcation
kit was used in the study. Anti-HCV was purchased from
ACON laboratories, USA.
Result: Out of 212 patients who had HCV quantiﬁed only
35 were also checked for HCV antibody. Patients were
divided in high viral load >2 million HCV copies/ml, and
low-intermediate <2 million HCV copies/ml. we checked for
liver function tests in both groups. Only 3.1% of patients
in the high group had normal liver enzymes (AST< 30 IU),
while 47% had normal liver enzymes in low-intermediate
group. Average ALT 45 IU in low-intermediate group. Mean
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platelet number was 198000 in high, and 213000 in low-
intermediate group. Out of 35 patients who were checked
for both HCVRNA and Anti-HCV 68.5% (n = 24) positive for
both Anti-HCV and HCVRNA, while 31.5% were positive for
anti-HCV but HCVRNA negative. These patients are believed
to be immune to HCV.
Conclusion: With the introduction of HCV quantiﬁcation
method as a diagnostic tool, it became possible to
distinguish truly HCV immune patients who were considered
as HCV infected before. We noticed positive correlation HCV
viral load with liver enzymes. The method allows treatment
monitoring for the ﬁrst time in Mongolia.
PP-144 Inﬂuence of predictor variables on side effects
of the treatment with PEG Interferon Alfa 2a
plus ribavirin in chronic hepatitis C
N. Sargsyants1 *. 1Armenicum Clinical Center, Yerevan,
Armenia
Aim: Prediction of main side effects of chronic hepatitis C
treatment with Peg-IFN a2a and ribavirin.
Methods: We evaluated in 55 patients treated with
Peg-IFN a-2a plus ribavirin numerous predictors inﬂuence
on main side effects (dichotomous dependent variable) on
different date of therapy: ﬂu-like syndrome, leucopenia,
thrombocytopenia, weigh lose, fatigue, depression,
insomnia, artralgia, myalgia, anorexia, nausea, anemia,
headache, alopecia, pruritus and rash. Statistic analyses
was done by SPSS 11.0 with binary logistic regression. Eleven
independent variables, such as age, gender, body mass in-
dex (BMI), disease limitation, pretreatment with standard or
Peg-IFN, presence of antibodies to HBV, alcohol abuse, drug
abuse, genotype (1b, 1a, 2 and 3), level of ferritin (FERR),
viral load (VL), were coding as dichotomous or categorical.
Results: Already on ﬁrst month of the treatment probability








where HBV(1) HBcAb; disease limitation(1) long-standing
of HCV-infection up to 5 years; disease limitation(2) 5 10
years. Probability of ﬂu-like syndrome on ﬁrst month of





+ 2.69 genotype 1a
+ 8.07 genotype 2
+ 2.38 genotype 3
+ 2.67 high VL
1.94 alcohol abuse.
(2)
Risk factors were genotype 1a (OR = 14.7) and highVL
(OR = 1.45).
Signiﬁcant model was received for IVDU (p = 0.005), alcohol
abuse, HBV infection, high FERR and VL inﬂuence on weight




= 1.73 4.36 IVDU 1.78 high FERR
0.038 high VL 0.096 alcohol abuse
+ 1.55HBcAb.
(3)
Conclusions: Development of side effects of the treatment
with pegylated IFN-alfa-2a and ribavirin depends on some
predictor factors.
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Introduction: There is a growing evidence of intergenotypic
recombination in HCV. In this paper we report a patient
infected by HCV 1b and, probably, recombinant 2/1b that is
detected in peripheral blood mononuclear cells (PBMC).
Case description: Patient S., male, 31 years old admitted
in January 2009. HCV viral load in serum before treatment
9,630,000 IU/ml. HCV genotyping by sequencing 5′UTR and
NS5A. According to phylogenetic analysis NS5A belongs to 1b
(sera and PMBC), 5′UTR from serum to 1b, from PBMC to
genotype 2. Due to discordant results recombinant 2/1b
in PBMC can be suspected. NS5A interferon sensitivity
determining region (ISDR) contains mutation R2218H.
Laboratory: ALT 71U/l, AST 62U/l, GGT 36U/l. Liver
biopsy: HAI 8, ﬁbrosis 1. Immunohistochemically HCV NS3
was detected in lobules and tracts. Elevated CD16 and
CD20 was found in lymphoid follicules of portal tracts.
Patient received treatment with pegintron (1.5mg/kg BW)
plus ribavirin (1000mg/day) for 48 weeks. Virological and
biochemical response were achieved on 12 wk and remained
until the end of treatment and during follow-up. Liver biopsy
after treatment: HAI 3, ﬁbrosis 0. Immunohistochemically
NS3 was still detected in lobules and tracts, CD16 and CD20
decreased in portal tracts.
